Description:
Learn practical strategies to recognize, monitor, and manage cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk associated with bispecific antibody therapy in multiple myeloma, with an emphasis on patient safety and care coordination.
Learning Objectives:
- Identify the signs, grading, and early management strategies for CRS and ICANS
- Apply appropriate monitoring tools and interventions
Instructor:
Mary Steinbach, DNP, APRN
Featured
Visit Myeloma University
Created by the International Myeloma Foundation's Nurse Leadership Board, Myeloma University is an educational series for nurses and other healthcare professionals to gain knowledge about multiple myeloma.
Disclaimer:
The information contained in this website does not constitute medical advice, diagnosis or treatment and is for informational purposes only. The information in this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. If you think you may have a medical emergency, call your doctor or 911 immediately.
With support from:
Bristol Myers Squibb, GSK, and Sanofi
